PDCD1 and Skin rash: Different from the previous analyses (Figure 2(b)), the incidence risk of rash was higher when PD-1 or PD-L1 together with chemotherapy was given as the second-line option (OR = 2.98, 95% CI: [1.87, 4.75]; Chi2 = 3.95, p=0.05; Figure 3(b)) [74, 96].